None listed
Conditions
Brief summary
Hypothesis: MSCs are safe in COPD. Aims of trial ; To track MSCs post-infusion in the lung To ensure safety of MSCs We will infuse labelled MSCs and track them with nuclear imaging. We will then do a second infusion of MSCs to monitor safety
Interventions
This is a safety study looking at the role of mesenchymal stem cells (MSCs) in the treatment of Chronic Pulmonary Pulmonary Disease (COPD). We will give COPD patients 2 infusions of MSCs. The first infusion will have labelled MSCs with Indium. Following the infusion, MSCs will be tracked using nuclear medicine imaging for 5 days. Thereafter, there will be a second infusion of unlabelled MSCs. Patients will be then followed up at clinics with particular assessment of symptoms, quality of life, lu
This is a safety study looking at the role of mesenchymal stem cells (MSCs) in the treatment of Chronic Pulmonary Pulmonary Disease (COPD). We will give COPD patients 2 infusions of MSCs. The first infusion will have labelled MSCs with Indium. Following the infusion, MSCs will be tracked using nuclear medicine imaging for 5 days. Thereafter, there will be a second infusion of unlabelled MSCs. Patients will be then followed up at clinics with particular assessment of symptoms, quality of life, lung function and imrpoved well being. The dose of MSC infusion (2 x 10 million/kg) per each of the two doses over 2 hours. The second dose will be at day 7. The MSCS are labelled with indium a radio-label. Therefore the stem cells will be tracked by scanning the patient and identifying the location of the stem cells on scans. There is no controls to the study.
Sponsors
Royal Perth Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
60 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
COPD Moderate to severe COPD (GOLD 2-3)
Exclusion criteria
Inability to give consent Cardiac failure Renal failure Liver failure Active cancer
Outcome results
None listed